Similarly, the SURMOUNT trials evaluating tirzepatide for weight management in adults with obesity did not demonstrate a signal for erectile problems compared to placebo in reported adverse events

Durability of Results: Maintenance Studies: Tirzepatide (SURMOUNT-3): Continued treatment: Additional 5.5% weight loss Stopped treatment: Regained 14% of weight Conclusion: Need ongoing treatment Semaglutide (STEP-4): Continued treatment: Maintained loss, continued losing Stopped treatment: Regained most weight Conclusion: Need ongoing treatment Phentermine: FDA-approved for 12 weeks only Weight regain after stopping is universal Not a long-term solution All Weight Loss Medications: Obesity is chronic disease Medications treat symptoms, dont cure Stopping medication weight regain Long-term or indefinite use necessary for sustained results Safety Profile Comparison: Discontinuation Due to Side Effects: Tirzepatide: 6.2% Semaglutide: 6.9% Liraglutide: 9.9% Naltrexone-bupropion: 25% (very high) Orlistat: 15-20% Phentermine-topiramate: 8-10% GLP-1s have excellent tolerability considering their effectiveness
Navya PN, Kaphle A, Srinivas SP, Bhargava SK, Rotello VM, Daima HK
Examples licensed and available in the UK include semaglutide (Ozempic for injection, Rybelsus tablets), dulaglutide (Trulicity), liraglutide (Victoza), exenatide (Byetta), and lixisenatide (Lyxumia)
The entire compounded tirzepatide market was effectively shut down in a matter of months